AVITA Medical Raises 2026 Revenue Guidance on Strong Q2 Growth
Event summary
- Q2 revenue grew 18% YoY and 13% sequentially to $21.7M, driven by RECELL, Cohealyx, and PermeaDerm.
- Gross profit margin increased to 81.9%, up 70 bps YoY, despite portfolio expansion.
- Operating expenses decreased 6% YoY to $24.6M, with net cash use improving to $3.2M from $9.9M in Q1.
- Raised full-year 2026 revenue guidance to $86M–$89M (prior: $80M–$85M).
- Expects cash flow breakeven in Q4 2026.
The big picture
AVITA Medical's strong Q2 performance reflects its ability to scale commercial execution across multiple products while maintaining high margins. The proposed CMS reimbursement changes for RECELL could further accelerate adoption, positioning the company for sustained growth in the acute wound care market. The shift toward cash flow breakeven by year-end marks a pivotal phase in operational maturity.
What we're watching
- Regulatory Tailwinds
- CMS's proposed 2027 Medicare payment updates for RECELL could standardize reimbursement, boosting adoption.
- Product Diversification
- Cohealyx and PermeaDerm are gaining traction; their growth trajectory will determine portfolio balance.
- Cash Flow Inflection
- Whether AVITA can sustain operating discipline to achieve Q4 cash flow breakeven remains critical.
Related topics